Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| QVA149 | Experimental | QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks. |
|
| fluticasone/salmeterol | Active Comparator | Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| QVA149 | Drug | QVA149 via inhaler twice a day |
| |
| fluticasone/salmeterol |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve (AUC) 0-12 hours for FEV1 following 12 weeks of treatment | Area under the curve (AUC) 0-12 hours for Forced Expiratory Volume in 1 second (FEV1) following 12 weeks of treatment. AUC will be calculated using the trapezoidal rule and standardized with respect to length of time from the first 5 minute to the last measurement at 12 hours | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Trough Forced Expiratory Volume in 1 second (FEV1) following 12 weeks of treatment | Spiromtery testing conducted according to internationally accepted standards. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough FEV1 will be will be defined as the mean from repeat measurements at Day 1 and week 12 |
Not provided
Inclusion Criteria: - Age >= 40 years, patients with airflow limitation indicated by post-bronchdilation FEV1 >=30% and <80% of predicted normal, current or ex-smokers with a 10 pack year smoking history, patients with a mMRC grade 2 or greater Exclusion Criteria: - prolonged QTCF >450 ms, paroxysmal atrial fibrillation, Type I or uncontrolled Type II diabetes, history of asthma, COPD diagnosis before age 40, receiving treatments not allowed in the study, other concomitant pulmonary diseases.
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Buenos Aires | Buenos Aires | 1425 | Argentina | ||
| Novartis Investigative Site |
Not provided
Not provided
Not provided
Not provided
| Drug |
fluticasone/salmeterol via inhaler twice a day |
|
| Day 1 and Week 12 |
| Peak Forced Expiratory Volume in 1 second (FEV1) within 4 hours post-dose | Spirometry testing conducted accorded to internationally accepted standards. Peak FEV1 defined as the maximum FEV1 during the first 4 hours post dosing. The Peak FEV1 will be defined as the mean from repeat measurements at Day 1 and week 12. | Day 1 and Week 12 |
| Area under the curve (AUC) 0-4 hours for FEV1 | Area under the curve (AUC) 0-4 hours for Forced Expiratory Volume in 1 second (FEV1) at Day 1 and week 12. AUC will be calculated using the trapezoidal rule and standardized with respect to length of time from the first 5 minute to the last measurement at 12 hours. | Day 1 and Week 12 |
| Transition Dyspnea Index (TDI) Focal Score | Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline; negative scores indicate deterioration. A TDI focal score of 1 unit is considered to be a minimal clinically important difference (MCID) from baseline. | Week 12 |
| Quality of Lfe Assessment with St George's Respiratory Questionaire (SGRQ) | SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Change from baseline in total score will be assessed. | Week 12 |
| Change from baseline in daily number of puffs of rescue medication | Number of puffs of rescue medication in previous 12 hours is recorded in Patient Diary twice daily. The total number of puffs of rescue medication per day (daily use) over the active treatment period will be used to derive the mean daily number of puffs of rescue medication taken by the patient. | Week 12 |
| Daily symptoms reported by patient | Patient's daily symptoms will be recorded twice daily using a patient diary. Mean daily total symptom score, mean morning and evening symptom score for each patient will be calculated over the 12 week study period. | Week 12 |
| COPD assessment (CAT) test | COPD assessment test (CAT) contains 8 questions regarding patient symptoms. Patient will complete questions using a 6 point scale and total score out of a possible score of 40 will be summed and reported. | Week 12 |
| Safety and tolerability | All adverse events and serious adverse events (SAEs) will be reported. | Over 12 weeks |
| Buenos Aires |
| Buenos Aires |
| C1115AAB |
| Argentina |
| Novartis Investigative Site | Buenos Aires | Buenos Aires | C1122AAK | Argentina |
| Novartis Investigative Site | Buenos Aires | Buenos Aires | Argentina |
| Novartis Investigative Site | Mendoza | Mendoza Province | 5500 | Argentina |
| Novartis Investigative Site | Mendoza | Mendoza Province | M5500CBA | Argentina |
| Novartis Investigative Site | San Miguel de Tucumán | Tucumán Province | 4000 | Argentina |
| Novartis Investigative Site | Antwerp | 2060 | Belgium |
| Novartis Investigative Site | Brussels | 1000 | Belgium |
| Novartis Investigative Site | Genk | 3600 | Belgium |
| Novartis Investigative Site | Gilly | 6060 | Belgium |
| Novartis Investigative Site | Hasselt | 3500 | Belgium |
| Novartis Investigative Site | Jambes | 5100 | Belgium |
| Novartis Investigative Site | Barranquilla | Colombia |
| Novartis Investigative Site | Florida Blanca | Colombia |
| Novartis Investigative Site | Medellín | Colombia |
| Novartis Investigative Site | Cvikov | Czech Republic | 471 54 | Czechia |
| Novartis Investigative Site | Jindřichův Hradec | Czech Republic | 377 01 | Czechia |
| Novartis Investigative Site | Karlovy Vary | Czech Republic | 360 66 | Czechia |
| Novartis Investigative Site | Kuřim | Czech Republic | 664 34 | Czechia |
| Novartis Investigative Site | Pardubice | Czech Republic | 530 09 | Czechia |
| Novartis Investigative Site | Teplice | Czech Republic | 415 01 | Czechia |
| Novartis Investigative Site | Kyjov | CZE | 697 70 | Czechia |
| Novartis Investigative Site | Guntur | Andhra Pradesh | 522 001 | India |
| Novartis Investigative Site | Ahmedabad | Gujarat | 380 008 | India |
| Novartis Investigative Site | Faridabad | Haryana | 121 001 | India |
| Novartis Investigative Site | Karamsad | India | 388225 | India |
| Novartis Investigative Site | Bangalore | Karnataka | 560 002 | India |
| Novartis Investigative Site | Nagpur | Maharashtra | 400 012 | India |
| Novartis Investigative Site | Pune | Maharashtra | 411004 | India |
| Novartis Investigative Site | Jaipur | Rajasthan | 302004 | India |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C554862 | indacaterol-glycopyrronium combination |
| D000068297 | Fluticasone-Salmeterol Drug Combination |
| ID | Term |
|---|---|
| D000068299 | Salmeterol Xinafoate |
| D000420 | Albuterol |
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D000588 | Amines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000068298 | Fluticasone |
| D000730 | Androstadienes |
| D000736 | Androstenes |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided